Epirubicin
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | ELLENCE | — | 2005-03-02 | fda.gov ↗ |
| Approved | US (FDA) | ELLENCE | — | 1999-09-15 | fda.gov ↗ |
Trials 258 · started per year
Also used as a comparator or background therapy in 290 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials | ||||||
| Phase 1 | NCT07688252 Background | Jul 2026 → Dec 2032 expected | neuroblastoma | Chang Gung Memorial Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06121570 Background | Nov 2023 → Aug 2026 overdue | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 1 | NCT02527746 Background | Dec 2012 → Dec 2013 | breast cancer, neutropenia | EVIVE Biotechnology | Completed | No outcome recorded |
| Phase 1 | NCT01624441 Background | Aug 2012 → Sep 2013 | male breast carcinoma, triple-negative breast carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT02867397 Background | Jan 2012 → Aug 2015 | — | Disphar International B.V. | Completed | No outcome recorded |
| Phase 1 | NCT01386346 Background | Jun 2011 → Aug 2014 | cardia cancer, esophageal cancer | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 1 | NCT01880385 Background | Mar 2011 → Sep 2013 | inflammatory breast carcinoma | Association Tunisienne de lutte Contre le Cancer | Unknown | No outcome recorded |
| Phase 1 | NCT00822848 Background | Feb 2009 → Sep 2012 | sarcoma | OHSU Knight Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00872625 Background | Apr 2007 → Apr 2009 | female breast carcinoma | Centre Antoine Lacassagne | Completed | No outcome recorded |
| Phase 1 | NCT00113581 Background | Oct 2002 → May 2006 | esophageal cancer, gastric cancer | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1/29 trials | ||||||
| Phase 1/2 | NCT06739265 Background | Sep 2024 → Sep 2026 expected | peripheral T-cell lymphoma, not otherwise specified | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06421948 Comparator | May 2024 → May 2027 expected | peripheral T-cell lymphoma, not otherwise specified | Yanyan Liu | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05981014 Background | Aug 2023 → Dec 2030 expected | breast neoplasm | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01936064 Comparator | Oct 2016 → Oct 2017 | hematologic disorder | Lagos State University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02987244 Background | Mar 2016 → Mar 2020 | T-cell non-Hodgkin lymphoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT02638857 Background | Sep 2015 → Mar 2017 | hepatocellular carcinoma | Second Military Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT00954512 Background | Sep 2009 → Jun 2011 | neoplasm | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1/2 | NCT00719550 Background | Feb 2009 → Nov 2010 | esophageal cancer, gastric cancer, gastroesophageal junction adenocarcinoma | Amgen | Completed | No outcome recorded |
| Phase 1/2 | NCT00667420 Background | Apr 2008 → Jun 2011 | esophageal adenocarcinoma, gastric adenocarcinoma | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 2125 trials | ||||||
| Phase 2 | NCT07410559 Comparator | Jul 2026 → Apr 2029 expected | female breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07372079 Background | Apr 2026 → Dec 2028 expected | breast cancer | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07378306 Background | Mar 2026 → Jun 2029 expected | breast cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07342283 Background | Feb 2026 → Dec 2027 expected | triple-negative breast carcinoma | Affiliated Hospital of Nantong University | Recruiting | No outcome recorded |
| Phase 2 | NCT07410234 Background | Feb 2026 → Feb 2028 expected | breast cancer | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Show all 125 trials opens the full record — a long page | ||||||
| Phase 2/314 trials | ||||||
| Phase 2/3 | NCT06009627 Comparator | Apr 2023 → Mar 2025 | breast cancer | Tianjin Medical University Cancer Institute and Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT05253066 Comparator | Feb → Jul 2022 | breast neoplasm | Shengjing Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT04290793 Comparator | Mar 2020 → Dec 2026 expected | breast cancer | Hebei Medical University Fourth Hospital | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT01907529 Comparator | Aug 2019 → Aug 2020 | female breast carcinoma | Hebei Medical University Fourth Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT03696004 Comparator | Dec 2018 → Jun 2019 | breast cancer | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03507465 Comparator | Nov 2017 → Nov 2019 | breast cancer | Guangdong Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02871869 Background | Sep 2016 → Sep 2018 | diffuse large B-cell lymphoma | Xinjiang Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01404156 Comparator | Sep 2015 → Aug 2023 | esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | Dr. Gordon Buduhan | Completed | No outcome recorded |
| Phase 2/3 | NCT01433562 Background | Aug 2011 → Nov 2012 | breast cancer | Dexa Medica Group | Completed | No outcome recorded |
| Phase 2/3 | NCT01216644 Comparator | Aug 2010 → Mar 2017 | gastric cancer | Krankenhaus Nordwest | Completed | No outcome recorded |
| Phase 2/3 | NCT00930891 Background | Sep 2009 → Jul 2012 | small cell lung carcinoma | French Cooperative Thoracic Intergroup | Completed | No outcome recorded |
| Phase 2/3 | NCT01150513 Comparator | Jun 2009 → Jan 2016 | breast cancer | Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT01204437 Comparator | Mar 2009 → Jan 2014 | breast cancer | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 2/3 | NCT00450203 Background | Oct 2007 → Dec 2017 | gastroesophageal cancer | Medical Research Council | Unknown | No outcome recorded |
| Phase 398 trials | ||||||
| Phase 3 | NCT07424287 Comparator | Jul 2026 → Jun 2030 expected | urinary bladder carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07441460 Background | Mar 2026 → Aug 2034 expected | HER2 positive breast carcinoma | Shanghai JMT-Bio Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06966700 Background | Jun 2025 → Mar 2033 expected | triple-negative breast carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06977893 Background | Mar 2025 → Mar 2027 expected | hormone receptor-positive breast cancer | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
| Phase 3 | NCT06795503 Comparator | Feb 2025 → Aug 2028 expected | triple-negative breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06627712 Background | Nov 2024 → Nov 2029 expected | triple-negative breast carcinoma | West China Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06144944 Background | Jan 2024 → Jun 2026 overdue | female breast carcinoma, hormone receptor-positive breast cancer, invasive breast carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06112379 Background | Nov 2023 → Nov 2028 expected | breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05909332 Background | Jun 2023 → May 2029 expected | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05883852 Comparator | Jun 2023 → Jul 2031 expected | HER2 positive breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05901428 Comparator | Jun 2023 → Jun 2026 overdue | hormone receptor-positive breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05862064 Background | Jun 2023 → Jul 2026 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT06441110 Background | Jun 2023 → Jun 2025 overdue | urinary bladder neoplasm | Fujian Medical University Union Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT05678933 Background | Jan 2023 → Dec 2027 expected | peripheral T-cell lymphoma, not otherwise specified | Tianjin Medical University Cancer Institute and Hospital | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT05472896 Comparator | Jun 2022 → Jun 2024 | hepatocellular carcinoma | Gao-jun Teng | Unknown | No outcome recorded |
| Phase 3 | NCT04947059 Comparator | Dec 2021 → Oct 2025 overdue | urinary bladder cancer | University of Thessaly | Recruiting | No outcome recorded |
| Phase 3 | NCT05075460 Background | Oct 2021 → May 2024 | T-cell non-Hodgkin lymphoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04736394 Comparator | Sep 2021 → Mar 2025 | non-invasive bladder urothelial carcinoma | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Unknown | No outcome recorded |
| Phase 3 | NCT05164770 Comparator | Mar 2021 → Dec 2023 | high grade B-cell lymphoma, high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement, mantle cell lymphoma | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04613674 Background | Dec 2020 → Sep 2023 | triple-negative breast carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04301739 Background | Apr 2020 → Sep 2022 overdue | triple-negative breast carcinoma | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04296175 Comparator | Mar 2020 → Mar 2025 overdue | triple-negative breast carcinoma | Fudan University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04193059 Comparator | Dec 2019 → Jul 2026 overdue | breast cancer | Fudan University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04335669 Comparator | Dec 2019 → Sep 2035 expected | triple-negative breast carcinoma | Lund University Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03876886 Comparator | Feb 2019 → Feb 2024 | triple-negative breast carcinoma | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT03725059 Background | Dec 2018 → Jan 2031 expected | breast cancer | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03498716 Background | Aug 2018 → Aug 2023 | triple-negative breast carcinoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 3 | NCT03556358 Background | Jun 2018 → Nov 2020 | HER2 positive breast carcinoma | Tanvex BioPharma USA, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03013504 Background | Feb 2018 → Apr 2019 | HER2 positive breast carcinoma | Prestige Biopharma Limited | Completed | No outcome recorded |
| Phase 3 | NCT03201861 Comparator | Jul 2017 → Aug 2027 expected | breast mucinous carcinoma, invasive tubular breast carcinoma | RenJi Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT03192644 Comparator | Jul 2017 → Dec 2022 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT04490993 Comparator | Mar 2017 → May 2022 | urinary bladder carcinoma | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Unknown | No outcome recorded |
| Phase 3 | NCT03036488 Background | Mar 2017 → Oct 2025 | triple-negative breast carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02971345 Background | Jan 2017 → Oct 2020 | hepatocellular carcinoma, portal vein thrombosis | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02973685 Comparator | Oct 2016 → Nov 2020 | hepatocellular carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT02767674 Comparator | May 2016 → Dec 2020 | diffuse large B-cell lymphoma | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT02620280 Background | Apr 2016 → Jan 2024 | invasive ductal breast carcinoma | Fondazione Michelangelo | Completed | No outcome recorded |
| Phase 3 | NCT02586025 Background | Mar 2016 → Oct 2017 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02455141 Background | Mar 2016 → Mar 2027 expected | breast neoplasm | Shanghai Jiao Tong University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02535221 Comparator | Jul 2015 → Jun 2026 overdue | breast cancer | Peking University | Recruiting | No outcome recorded |
| Phase 3 | NCT02395640 Comparator | Mar 2015 → Feb 2021 | gastric cancer | Fudan University | Completed | No outcome recorded |
| Phase 3 | NCT02125344 Comparator | Dec 2014 → Nov 2016 | HER2 positive breast carcinoma, breast mucinous carcinoma, female breast carcinoma, inflammatory breast carcinoma +1 | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 3 | NCT02042690 Comparator | Jul 2014 → Feb 2018 | acute lymphoblastic leukemia | Peking University | Completed | No outcome recorded |
| Phase 3 | NCT02755311 Comparator | Mar 2014 → Jun 2016 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT01966471 Background | Jan 2014 → Nov 2019 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02879513 Comparator | Jan 2014 → Jun 2020 | breast mucinous carcinoma, inflammatory breast carcinoma, invasive tubular breast carcinoma | RenJi Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01996267 Comparator | Dec 2013 → Dec 2018 overdue | HER2 positive breast carcinoma | The Netherlands Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01675219 Background | Dec 2012 → Dec 2021 | urinary bladder cancer | Turku University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02001506 Comparator | Nov 2012 → Dec 2015 | breast cancer | Asan Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01697072 Background | Oct 2012 → Nov 2014 | gastric cancer | Amgen | Terminated | No outcome recorded |
| Phase 3 | NCT01642771 Comparator | Jun 2012 → Dec 2019 | breast cancer | China Breast Cancer Clinical Study Group | Unknown | No outcome recorded |
| Phase 3 | NCT01358877 Background | Nov 2011 → Dec 2016 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01479036 Comparator | Oct 2011 → Dec 2014 | breast cancer | Xijing Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01710176 Comparator | Jun 2011 → Jun 2024 | soft tissue sarcoma | Italian Sarcoma Group | Completed | No outcome recorded |
| Phase 3 | NCT01354522 Comparator | May 2011 → Dec 2023 | breast cancer | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01327521 Background | Feb 2011 → Feb 2014 | hepatocellular carcinoma | Albert Koong | Withdrawn | No outcome recorded |
| Phase 3 | NCT01216111 Comparator | Jan 2011 → Apr 2016 | triple-negative breast carcinoma | Fudan University | Completed | No outcome recorded |
| Phase 3 | NCT04031703 Comparator | Jan 2011 → Apr 2016 | breast cancer | Fudan University | Completed | No outcome recorded |
| Phase 3 | NCT01204801 Background | Nov 2010 → Dec 2016 | breast cancer | Medifocus, Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT01134523 Comparator | May 2010 → May 2018 | breast cancer | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT01026116 Background | Dec 2009 → Jan 2016 | breast cancer | Fudan University | Completed | No outcome recorded |
| Phase 3 | NCT00950300 Background | Oct 2009 → Jul 2011 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01053390 Background | Oct 2009 → Dec 2013 | gallbladder carcinoma | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 3 | NCT01094964 Background | Oct 2009 → Oct 2013 | urinary bladder cancer | Cancer Research Campaign Clinical Trials Centre | Unknown | No outcome recorded |
| Phase 3 | NCT01093235 Background | Apr 2009 → Apr 2012 | breast cancer, chemotherapy-induced toxicity | Cambridge University Hospitals NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 3 | NCT01049425 Comparator | Feb 2009 → Mar 2017 | Her2-receptor negative breast cancer | West German Study Group | Completed | No outcome recorded |
| Phase 3 | NCT00847444 Comparator | Feb 2009 → Sep 2011 | breast cancer | Philip Hepp | Unknown | No outcome recorded |
| Phase 3 | NCT00718354 Comparator | Jul 2008 → Jan 2010 | gastric cancer, gastroesophageal cancer | Thrombosis Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT00670878 Background | Jun 2008 → Oct 2011 | breast cancer | Ludwig-Maximilians - University of Munich | Completed | No outcome recorded |
| Phase 3 | NCT00689156 Comparator | Jun 2008 → Jan 2013 | breast neoplasm | Danish Breast Cancer Cooperative Group | Completed | No outcome recorded |
| Phase 3 | NCT00776724 Comparator | May 2008 → Nov 2014 | breast cancer | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00824785 Comparator | May 2008 → Feb 2013 | gastroesophageal cancer | Royal Marsden NHS Foundation Trust | Terminated | No outcome recorded |
| Phase 3 | NCT00625898 Background | Apr 2008 → Jun 2013 | breast cancer | NSABP Foundation Inc | Terminated | No outcome recorded |
| Phase 3 | NCT00593697 Comparator | Jan 2008 → Nov 2014 | breast cancer | Finnish Breast Cancer Group | Completed | No outcome recorded |
| Phase 3 | NCT00567554 Background | Oct 2007 → Aug 2011 | breast cancer | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 3 | NCT01985724 Comparator | Oct 2007 → Dec 2013 | breast cancer | Hellenic Oncology Research Group | Completed | No outcome recorded |
| Phase 3 | NCT00630032 Background | Sep 2007 → Jun 2017 | breast cancer | UNICANCER | Completed | No outcome recorded |
| Phase 3 | NCT00407186 Comparator | Jan 2007 → Dec 2018 | gastric cancer | Dutch Colorectal Cancer Group | Unknown | No outcome recorded |
| Phase 3 | NCT00262067 Background | Dec 2005 → Jul 2008 | breast cancer | Genentech, Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT02181101 Background | Sep 2005 → Sep 2013 | breast neoplasm | Ludwig-Maximilians - University of Munich | Completed | No outcome recorded |
| Phase 3 | NCT00309556 Comparator | Feb 2005 → Nov 2009 | breast cancer | Austrian Breast & Colorectal Cancer Study Group | Completed | No outcome recorded |
| Phase 3 | NCT00288002 Background | Jan 2005 → ? | breast cancer | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00615602 Background | Oct 2004 → May 2012 | female breast carcinoma | Hellenic Oncology Research Group | Completed | No outcome recorded |
| Phase 3 | NCT00431080 Background | Aug 2004 → Oct 2007 | breast cancer | Hellenic Oncology Research Group | Completed | No outcome recorded |
| Phase 3 | NCT00129935 Background | Feb 2004 → Jun 2013 | breast cancer | Spanish Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 3 | NCT00336791 Background | Sep 2003 → Aug 2007 | breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00311636 Background | Sep 2003 → Jan 2008 | breast cancer | Gruppo Italiano Mammella (GIM) | Completed | No outcome recorded |
| Phase 3 | NCT01433614 Comparator | Dec 2002 → Jun 2006 | breast cancer | Thomas Hatschek | Completed | No outcome recorded |
| Phase 3 | NCT00039546 Background | Aug 2001 → ? | breast cancer | Cancer Research Campaign Clinical Trials Centre | Unknown | No outcome recorded |
| Phase 3 | NCT02288741 Background | Aug 2001 → Sep 2012 | plasma cell myeloma | WiSP Wissenschaftlicher Service Pharma GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00038402 Background | Apr 2001 → Nov 2004 | breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00014222 Comparator | Dec 2000 → Feb 2014 | breast cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 3 | NCT02324088 Background | Oct 2000 → Dec 2012 | inflammatory breast carcinoma | UNICANCER | Completed | No outcome recorded |
| Phase 3 | NCT00668616 Comparator | Mar 2000 → Jul 2005 | female breast carcinoma | North Eastern German Society of Gynaecological Oncology | Completed | No outcome recorded |
| Phase 3 | NCT02450058 Comparator | Nov 1996 → May 2012 | breast cancer | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | Completed | No outcome recorded |
| Phase 3 | NCT00002784 Comparator | Jun 1996 → Aug 2011 | breast cancer | ETOP IBCSG Partners Foundation | Completed | No outcome recorded |
| Phase 3 | NCT00002870 Background | Dec 1994 → Jan 2002 | breast cancer | UNICANCER | Completed | No outcome recorded |
| Phase 3 | NCT00002542 Background | Jul 1993 → Mar 2007 | breast cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 413 trials | ||||||
| Phase 4 | NCT04136782 Comparator | Jul 2021 → Nov 2025 overdue | breast cancer | Shengjing Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04134247 Background | Nov 2019 → Nov 2021 | non-Hodgkin lymphoma | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04152577 Background | Jun 2019 → Oct 2021 | B-cell non-Hodgkin lymphoma | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03892330 Comparator | Jun 2019 → Dec 2020 overdue | childhood kidney Wilms tumor | Shengjing Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT03631862 Background | Sep 2018 → Dec 2019 | peripheral T-cell lymphoma, not otherwise specified | Zhengzhou University | Unknown | No outcome recorded |
| Phase 4 | NCT03558412 Background | Jun 2018 → Dec 2019 | T-lymphoblastic lymphoma | Mingzhi Zhang | Unknown | No outcome recorded |
| Phase 4 | NCT03123770 Comparator | Dec 2016 → Dec 2021 | breast cancer | Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT02688803 Comparator | Aug 2016 → Oct 2017 | breast cancer | Ottawa Hospital Research Institute | Terminated | No outcome recorded |
| Phase 4 | NCT02627248 Background | Oct 2015 → Oct 2025 | breast cancer | Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT02526823 Comparator | Aug 2015 → Dec 2019 | lymphoma | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02207361 Comparator | Dec 2013 → Nov 2016 | breast cancer | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01501487 Comparator | Oct 2011 → Feb 2016 | breast cancer | Agendia | Completed | No outcome recorded |
| Phase 4 | NCT00531973 Comparator | Jan 2007 → Aug 2008 | female breast carcinoma | Catholic University, Italy | Unknown | No outcome recorded |
| Phase not applicable21 trials | ||||||
| — | NCT07622836 Background | Jun 2026 → Jan 2030 expected | lymph node cancer, triple-negative breast carcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| — | NCT06975644 Background | Sep 2025 → Sep 2026 expected | triple-negative breast carcinoma | Zhejiang Provincial People's Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06102252 Comparator | Aug 2024 → Nov 2025 | endometrial carcinoma | Sohag University | Completed | No outcome recorded |
| — | NCT05914753 Background | Jul 2023 → Jun 2024 | breast cancer | Zhejiang Provincial People's Hospital | Unknown | No outcome recorded |
| — | NCT05547516 Comparator | Sep 2022 | non-invasive bladder urothelial carcinoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| — | NCT05296317 Background | Sep 2022 → Sep 2025 | breast carcinoma | Centre Georges Francois Leclerc | Completed | No outcome recorded |
| — | NCT05341141 Background | Jun 2022 → Aug 2026 overdue | breast cancer | Peking University | Recruiting | No outcome recorded |
| — | NCT05287308 Background | Mar 2022 → Sep 2027 expected | breast cancer | Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| — | NCT05146635 Comparator | Dec 2021 → Dec 2022 | urinary bladder cancer | Mansoura University | Unknown | No outcome recorded |
| — | NCT05053386 Comparator | Oct 2021 → Oct 2022 | hepatocellular carcinoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| — | NCT05656079 Comparator | Jul 2021 → Sep 2024 | breast cancer | Shanghai Pudong Hospital | Unknown | No outcome recorded |
| — | NCT04582955 Background | Oct 2020 → Dec 2022 | triple-negative breast carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| — | NCT04738188 Background | Mar 2020 → Nov 2022 | hepatocellular carcinoma | Beijing Tsinghua Chang Gung Hospital | Unknown | No outcome recorded |
| — | NCT05084586 Comparator | Oct 2019 → Oct 2023 | chemotherapy-induced toxicity, superficial urinary bladder carcinoma | Ankara Training and Research Hospital | Unknown | No outcome recorded |
| — | NCT04067102 Background | May 2019 → May 2021 | triple-negative breast carcinoma | Hebei Medical University Fourth Hospital | Withdrawn | No outcome recorded |
| — | NCT03756090 Background | Dec 2018 → Dec 2019 | breast cancer | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| — | NCT02760953 Comparator | Oct 2017 → Oct 2018 | urinary bladder neoplasm | Huashan Hospital | Unknown | No outcome recorded |
| — | NCT01503905 Comparator | Dec 2011 → May 2018 | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT00825669 Comparator | Dec 2008 → Dec 2009 | hepatocellular carcinoma | Eastern Hepatobiliary Surgery Hospital | Completed | No outcome recorded |
| — | NCT00462696 Background | Feb 2006 → Dec 2008 | female breast carcinoma | Institut Bergonié | Completed | No outcome recorded |
| — | NCT00309920 Background | Jan 2004 → ? | female breast carcinoma | Heinrich-Heine University, Duesseldorf | Unknown | No outcome recorded |
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 550 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epirubicin | “In the A arm, the combined treatment with irinotecan liposome (intravenous injection, once every two weeks for 1 month, dose increasing regimen: 37.6 mg/m2 and 56.5mg/m2) and...” NCT06766266 ↗524“Docetaxel 75 mg/m2, day 1 Epirubicin 80 mg/m2, day 1 Cyclophosphamide 500 mg/m2, day 1 Navelbine 25 mg/M2 in 250 cc NS over 60 min on day 1 and day 8 Bevacizumab 5 mg/kg in 100...” NCT00830544 ↗ “Epirubicin (90 mg/m², intravenous infusion) combined with cyclophosphamide (600 mg/m², intravenous infusion, every 2 weeks or 3 weeks, determined by investigators) for 4...” NCT07410559 ↗ “Anthracycline/taxane-based neoadjuvant regimen recommended by the NCCN or local guidelines. i.e. EC or AC (epirubicin 90 mg/m2 or doxorubicin 60 mg/m2 and cyclophosphamide 600...” NCT05569811 ↗ “a) Cyclophosphamide: 750 mg/m2 i.v. drip, administered on D1; b) Doxorubicin: 50 mg/m2 i.v. drip (or Epirubicin: 70mg/m2 i.v. drip), administered on D1; c) Vincristine: 1.4...” NCT06961500 ↗ “The chemotherapy included nab-paclitaxel (100 mg/m2) and carboplatin (area under the curve, 1.5) on days 1, 8, and 15 in 28-day cycles for the first 16 weeks followed by...” PMID 39671272 ↗ Feb 2025 “Standard new adjuvant treatment with toripalimab combined with chemotherapy, that is in the first phase consisting of paclitaxel and toripalimab for four cycles, followed by...” NCT06671262 ↗ “The anthracycline may be either Epirubicin (body surface area-adjusted 50 mg/m²) or Liposomal Doxorubicin (body surface area-adjusted 30 mg/m²) combined with Cyclophosphamide...” NCT06914440 ↗ “Six cycles of standard induction chemotherapy consisting of cyclophosphamide, vincristine, doxorubicin (or epirubicin), etoposide, and cisplatin administered according to the...” NCT07688252 ↗ “Fluorouracil 500-600 milligrams per square meter (mg/m2), epirubicin 90-120 mg/m2, and cyclophosphamide 500-600 mg/m2 by intravenous (IV) infusion every 3 weeks for three...” NCT02586025 ↗ “standard infusion chemotherapy (including gemcitabine, mitomycin, epirubicin, etc.), dissolved in 50 mL of normal saline or glucose, and intravesical infusion chemotherapy for...” NCT05547516 ↗ “Neoadjuvant chemotherapy regimen will consist of six cycles of fluorouracil 500mg/m2 , epirubicin 75mg/m2 and cyclophosphamide 500mg/m2 administered intravenously at three week...” NCT03696004 ↗ “Then the left and right hepatic arteries were accessed by a microcatheter and intraarterial epirubicin (40 mg) and oxaliplatin (150 mg) in a mixture of lipiodol (3～5 mL) were injected.” NCT02109146 ↗ “AC or EC (adriamycin or epirubicin and cyclophosphamide) or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles to be delivered after surgery” NCT02620280 ↗ “Epirubicin (E) 90\~100mg/m\^2, i.v., d1 + cyclophosphamide (C) 600 mg/m\^2, i.v., d1, q2w, for 4 cycles followed by albumin-paclitaxel (T) 260 mg/m\^2, i.v., d1, q2w, for 4 cycles.” NCT05341141 ↗ “will receive the TEC regimen: paclitaxel 150mg/m2 infused for 3 hours, epirubicin 50mg/m2 infused for 30 minutes, and carboplatin 4mg/ml/min for one hour on day 1 every 3 weeks.” NCT06102252 ↗ “Patients will be treated with six cycles of neoadjuvant chemotherapy combining epirubicin (75 mg/m² on day 1) and docetaxel (75 mg/m² on day 1), administered every 21 days” NCT00462696 ↗ “postoperative adjuvant chemotherapy (100 mg/m² Epirubicin + 600 mg/m² Cyclophosphamide) combined with 200 mg Sintilimab intravenously every 3 weeks for a total of 1 year.” NCT07351487 ↗ “The chemotherapy regimen is AC-T: epirubicin 100mg/m2, cyclophosphamide 600mg/m2, every 3 weeks for 4 cycles; followed by paclitaxel 80mg/m2, every week for 12 cycles.” NCT07197697 ↗ “Epirubicin (75-100 mg/m²) in combination with cyclophosphamide (600 mg/m²), administered by intravenous infusion every 21 days (Q3W), for a total of 4 cycles.” NCT07254858 ↗ “Ifosfamide (day 1-3: 1.900mg/m² iv), epirubicin (day 1: 75 mg/m² iv), etoposide (day 1-3: 120 mg/m² iv) and G-CSF (day 5 until end of apheresis: 5µg/kg sc)” NCT02288741 ↗ “FEC-D (5-FU 500 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 500 mg/m2 q3weeks x 3 cycles followed by docetaxel 100 mg/m2 q3weeks x 3 cycles)” NCT02688803 ↗ “docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles” NCT01354522 ↗ “Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 and Nab-paclitaxel 260mg/㎡ d1 of Cycles 1-6 (Q3W) of the neoadjuvant phase of the study; IV injection.” NCT04914390 ↗ “both Arms followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.” NCT02789332 ↗ “epirubicin 50 mg/m2 day 1, oxaliplatin 130 mg/m2 day 1, and 5-FU 375-425 mg/m2/d day 1 through 5 continuous infusion, repeated every 3 weeks” NCT00767377 ↗ “One vial of 300-500μm DC Bead was loaded with 50mg epirubicin, and after full drug loading, 10-20ml of non-ionic contrast agent was added.” NCT07016126 ↗ “3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100)” NCT02181101 ↗ “The standard chemotherapy regimen is the AC-T regimen (4 cycles of epirubicin plus cyclophosphamide, followed by 4 cycles of a taxane)” NCT07622836 ↗ “those who do not will receive QL1706 Q3W + epirubicin Q3W + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy before surgery.” NCT07372079 ↗ “Anthracycline usually use epirubicin, 90-100mg/m2, combine with Cyclophosphamide 600mg/m2, both use at day 1, every 3 weeks cycle.” NCT07317778 ↗ “Docetaxel plus trastuzumab for 9 weeks, followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide in both groups.” PMID 29852043 ↗ Sep 2018 “Epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks for 4 cycles (Cycles 5-8)” NCT04398914 ↗ “DEB-TACE(epirubicin 60mg) D1; Additional DEB-TACE procedures were carried out every 4-6 weeks based on tumor response.” NCT04174781 ↗ “The CHOP include cyclophosphamide, doxorubicin/Epirubicin/liposomal doxorubicin, vincristine/Vindesine, and prednison.” NCT05933967 ↗ “neoadjuvant FEC (fluorouracil, epirubicin, cyclophosphamide) followed by weekly paclitaxel and concomitant trastuzumab” NCT01340430 ↗ “epirubicin 30mg/m2 intravenous injection from 1 day to 2 , ifosfamide 1.8g/m2 intravenous injection from 1day to 5day” NCT03815474 ↗ “epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks 4 cycles (Cycles 5-8)” NCT04066790 ↗ “Epirubicin 100mg/m2 and cyclophosphamine 600mg/m2 for four cycles followed by paclitaxol 175mg/m2 for four cycles” NCT03242551 ↗ “Postoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1” NCT01787539 ↗ “cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/ m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1” NCT06674096 ↗ “Physician choice: anthracycline based chemotherapy including Adriamycin, Epirubicin give as standard of care” NCT02067416 ↗ “Docetaxel: 75mg/m2, d1, q3w\*6, Epirubicin 75mg/m2, d1, q3w\*6 and Cyclophosphamide: 500mg/m2, d1, q3w\*6” NCT02532400 ↗ “A: epirubicin, pirarubicin or doxorubicin. Routine clinical dosage and administration shall be adopted.” NCT07410234 ↗ “Unless medically contraindicated, an anthracycline-containing regimen using epirubicin should be given.” NCT00066807 ↗ “Epirubicin was administered intravenously after the dosage was calculated at 90mg/m2 body surface area” NCT06705127 ↗ “Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs.” NCT01204801 ↗ “5-Fluorouracil 500 mg/m2 IV day 1, Epirubicin 100 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1” NCT01501487 ↗ “oxaliplatin (100 mg) + epirubicin (50 mg) were injected into the hepatic artery by routine procedure” NCT04518852 ↗ “Epirubicin 90 mg/m² on Day 1 + Cyclophosphamide 600 mg/m² on Day 1, every 3 weeks (Q3W) × 4 cycles.” NCT06908668 ↗ “5FU 500mg/m2 + Epirubicin 75 mg/m2 + cyclophosphamide 500 mg/m2 IV on day 1 of 4 (21 day) cycles” NCT00524303 ↗ “Patients receive fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1.” NCT00433589 ↗ “standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2)” NCT01537536 ↗ “or TACE (epirubicin 50 mg, lobaplatin 50 mg, and lipiodol and polyvinyl alcohol particles).” PMID 34648352 ↗ Oct 2021 “Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2.” NCT06611813 ↗ “Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2.” NCT06977893 ↗ “Doxorubicin (or Epirubicin) can be modified according to national/institutional guidelines” NCT04031677 ↗ “Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2” NCT07383818 ↗ “Doxorubicin:IV infusion,60 mg/m2,q3w(OR Epirubicin:IV infusion,90 mg/m2,q3w);(13-24 week)” NCT07101614 ↗ “primary systemic therapy with epirubicin 25 mg/m2 intravenously (i.v.) on days 1 and 2” NCT00301548 ↗ “12-week EC regimen (epirubicin 80mg/m² + cyclophosphamide 600mg/m², IV Q3W, 4 cycles)” NCT07491822 ↗ “First Phase of Neoadjuvant Chemotherapy: Epirubicin + Cyclophosphamide + Toripalimab.” NCT06682195 ↗ “IV 5-Fluorouracil (500 mg/m2) Epirubicin (100 mg/m2) and Cyclophosphamide (500 mg/m2)” NCT01010854 ↗ “followed by 5-FU, epirubicin, and cyclophosphamide (FEC) every 3 weeks for 4 cycles” NCT00110695 ↗ “The chemotherapeutic drugs include 5-Fu 1500 mg, epirubicin 30 mg, cisplatin 30 mg.” NCT00825669 ↗ “5-fluorouracil (500 mg/m2), epirubicin (90 mg/m2), and cyclophosphamide (500 mg/m2)” PMID 30413379 ↗ Nov 2018 “Epirubicin + cyclophosphamide + Benmelstobart are administered by intravenous drip” NCT06874933 ↗ “Albumin Paclitaxel + Carboplatin\*4 Followed by Epirubicin + Cyclophosphamide\*4” NCT07256964 ↗ “single immediate post TUR-BT epirubicin (2mg/ml, total of 100 ml) instillation” NCT01675219 ↗ “Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle;” NCT06639672 ↗ “epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab” NCT04094896 ↗ “with 50 mg of chemotherapeutic agent epirubicin admixed with 5 ml lipiodol.” NCT00867750 ↗ “with optional epirubicin, 50 mg/m2, every 3 weeks before and after surgery” PMID 37856106 ↗ Dec 2023 “Postoperative immediate instillation of epirubicin (50mg) is administered.” NCT06441110 ↗ “Epirubicin,75mg/m2,intravenous ,on day 1 of each 21 day cycle, 4 cycles” NCT02539017 ↗ “Regimen A:CODOX-M:cyclophosphamide,epirubicin,vincristine,methotrexate.” NCT03558412 ↗ “A: Anthracyclines, including epirubicin, pirarubicin, and doxorubicin.” NCT07378306 ↗ “using 30 mg/m2 of epirubicin, 300mg/m2 carb mixed with 2-5 mL lipiodol” NCT07380633 ↗ “Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 Docetaxel 75mg/㎡ d1 1/21d” NCT04499118 ↗ “Etoposide 50mg/ m2, Epirubicin 15mg/ m2, Vincristine 0.4mg/ m2, d1-4” NCT05164770 ↗ “epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles” NCT05862610 ↗ “Anthracyclines (Doxorubicin or Epirubicin or Liposomal Doxorubicine)” NCT02299999 ↗ “and Epirubicin 75mg/m2, intravenous infusion，at day1 every 3 weeks” NCT04582955 ↗ “Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle” NCT06627712 ↗ “Epirubicin 90-100mg/m2 d1 q21d or Doxorubicin 50-60mg/m2 d1 q21d” NCT06802757 ↗ “in the R-CEOP70 group, epirubicin 70 mg/m2 replaced doxorubicin” PMID 31126528 ↗ Jun 2019 “Epirubicin (90mg/m2)+ cyclophosphamide (600mg/m2) 1/14d×4 cycle” NCT05871918 ↗ “Cycle 5-8: Doxorubicin or Epirubicin q3W + Cyclophospahmide q3W” NCT06358573 ↗ “Chemotherapeutic drugs: adriamycin，epirubicin and pirarubicin.” NCT03277716 ↗ “CHOP regimen(Cyclophosphamide,Vindesine,Epirubicin,Prednisone)” NCT03631862 ↗ “followed by four cycles of epirubicin (90 mg per square meter)” NCT06831955 ↗ “Fluorouracil Epirubicin Hydrochloride Cyclophonsphamide (FEC)” NCT03058939 ↗ “epirubicin: 75mg/m2 d1 (or liposomal doxorubicin 35mg/m2 d1)” NCT05290090 ↗ “Epirubicin is an anthracycline drug used for chemotherapy.” NCT05084586 ↗ “Doxorubicin 60 mg/m2 IV day 1 (or Epirubicin 75-100 mg/m2)” NCT05296746 ↗ “Epirubicin (EPI) 70mg / m2 intravenous infusion, day 1;” NCT05075460 ↗ “5-fluorouracil, epirubicin and cyclophosphamide [FEC]” PMID 29223479 ↗ Dec 2017 “doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1” NCT02838225 ↗ “Epirubicin (90 mg/m2), intravenously, every 21 days.” NCT04255056 ↗ “Epirubicin/Cyclophosphamide Followed by Docetaxel” NCT03507465 ↗ “Drug:Epirubicin 60mg/m2.d，d4,used in cycle 2,4,6” NCT02042690 ↗ “Epirubicin 100 mg/m² by 30 minutes i.v. infusion” NCT00256360 ↗ “Epirubicin 75mg/m2 by 30 minutes i.v infusion” NCT00286819 ↗ “Epirubicin: 90-100 mg/m², day 1, 21-day cycle” NCT07342283 ↗ “epirubicin (70 mg/m2 intravenously on day 1)” NCT06739265 ↗ “ECX (epirubicin, Cisplatin and Capecitabine)” NCT00113581 ↗ “epirubicin 100 mg/m² intravenously on d1” NCT00869284 ↗ “- Epirubicin + Cisplatin + Capecitabine” NCT00718354 ↗ “lobaplatin (30 mg) + epirubicin (40 mg)” NCT04273100 ↗ “followed by epirubicin-cyclophosphamide” NCT06977542 ↗ “epirubicin and 5-fluorouracil given IV” NCT00381706 ↗ “Epirubicin, 50-60 mg/m², ivgtt day 2” NCT05428670 ↗ “Epirubicin 100 mg/m2, every 3 weeks” NCT02001506 ↗ “Doxorubicin/Epirubicin 50 mg/m2 IV” NCT06890585 ↗ “Drug: Epirubicin 90 mg/m² given IV” NCT03799679 ↗ “epirubicin(Pharmorubicin) 50mg/m2” NCT01964027 ↗ “Epirubicin 75mg/m2 ivgtt on Day 1” NCT06394661 ↗ “epirubicin 70 mg/ m2, D1, iv.drip” NCT05572983 ↗ “DA-EPOCH：Epirubicin 15mg／m２ ,d1-4” NCT04134247 ↗ “Doxorubicin, Epirubicin, Eribulin” NCT02788201 ↗ “epirubicin (start dose 90mg/m2)” NCT00798070 ↗ “Epirubicin (75-100 mg/m2) iv D1” NCT05909332 ↗ “Epirubicin 90mg/m2 , ivgtt, d1” NCT05400993 ↗ “Epirubicin：70 mg/m2，ivgtt，D1 ；” NCT02526823 ↗ “Epirubicin 60 mg/㎡ iv days 1,8” NCT01917578 ↗ “epirubicin 50mg/m2 d1、8 ivgtt” NCT03513601 ↗ “Epirubicin 50 mg/m2 IV Day 2” NCT02358863 ↗ “epirubicin 90-100 mg/m\^2 IV” NCT00262067 ↗ “epirubicin (H) 75mg/m2 IV d1” NCT06158399 ↗ “epirubicin 70 mg/m2 i.v d 1” NCT00517894 ↗ “Epirubicin 50mg/m2 on day 1” NCT01558947 ↗ “epirubicin 70mg/m2 IV day 1” NCT00854568 ↗ “epirubicin (90mg/m² i.v.d1” NCT03201861 ↗ “Nab-paclitaxel+Epirubicin” NCT06967103 ↗ “Epirubicin 100 mg/m² i.v.” NCT00670878 ↗ “Doxorubicin or Epirubicin” NCT06371807 ↗ “Epirubicin: 75 mg/m2, d1” NCT05974085 ↗ “docetaxel and epirubicin” NCT04836156 ↗ “Epirubicin（60 mg/m2，d1）” NCT06569485 ↗ “Epirubicin 70 mg/m2 iv” NCT01433562 ↗ “Epirubicin 50mg/M2 D1” NCT00595972 ↗ “- Epirubicin 50 mg/m²” NCT02128243 ↗ “epirubicin: 90 mg/m2” NCT01150513 ↗ “Epirubicin 100 mg/m²” NCT02339532 ↗ “Epirubicin 15mg/ m2” NCT05097443 ↗ “Epirubicin 100 mg” NCT02527746 ↗ “Drug: Epirubicin” NCT06470633 ↗ “Drug: Epirubicin” NCT05491694 ↗ “Epirubicin” NCT00798070 ↗ “Epirubicin” NCT06705127 ↗ “epirubicin” NCT02363400 ↗ |
| Known as | 4'-epi-adriamycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL417 ↗ |
| Known as | 4'-epiDoxorubicin | “4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3” NCT00930891 ↗ |
| Known as | EADM | “Epirubicin(EADM)” NCT02638857 ↗ |
| Known as | Ellence | “Both epirubicin (Ellence); Pfizer Pharmaceuticals, New York, NY, http://www.pfizer.com) and thalidomide (Thalomid); Celgene Corporation, Warren, NJ, http://www.celgene.com)...” PMID 15967833 ↗ Jun 20051“Epirubicin (trade name Ellence)” NCT01204801 ↗ |
| Known as | EPI | “A: epirubicin, pharmorubicin (EPI) C: cyclophosphamide (CTX） T: paclitaxel (PTX）” NCT03876886 ↗2“Combination of Docetaxel (DTX) and Epirubicin (EPI)” NCT02392845 ↗ “Epirubicin (EPI) belongs to anthracyclines” NCT03151044 ↗ |
| Known as | Epiadriamycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL417 ↗ |
| Known as | Epidoxorubicin | “Treatment in this multicentric neoadjuvant pilot study consisted of panitumumab (9 mg/kg) for eight cycles q.3 weeks combined with four cycles of 5-fluorouracil, epidoxorubicin...” PMID 24827135 ↗ May 20144“Drug: Epidoxorubicin(15 mg/m2, iv, on days 1-4)” NCT01868828 ↗ |
| Known as | Epirubicin hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL417 ↗ |
| Known as | epirubicin hydrochloride | “To determine the pathologic response rate (\>= 95% necrosis) after preoperative treatment with sorafenib (sorafenib tosylate), epirubicin (epirubicin hydrochloride),...” NCT02050919 ↗33“Drugs used in chemotherapy, such as mitomycin C and epirubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by...” NCT01094964 ↗ “Patients with a poor response to docetaxal/herceptin will receive Fluorouracil, Epirubicin Hydrochloride, Cyclophonsphamide (FEC) injection by drip every 3 weeks.” NCT03879577 ↗ “Patients then receive standard chemotherapy comprising epirubicin hydrochloride IV, cyclophosphamide IV, and fluorouracil IV on day 1.” NCT00872625 ↗ “All patients receive epirubicin hydrochloride IV over 30-60 minutes and cyclophosphamide IV over 60 minutes on day 1.” NCT00288002 ↗ “Take epirubicin hydrochloride (90mg/m2, d1) every 14 days as one cycle for 4 cycles with cyclophosphamide” NCT04418154 ↗ “Patients receive epirubicin hydrochloride IV over 2 hours and carboplatin IV over 30 minutes on day 1” NCT00486356 ↗ “Patients receive epirubicin hydrochloride and cyclophosphamide in weeks 1-3.” NCT00379015 ↗ “Epirubicin hydrochloride for injection: 75mg/m2, intravenous drip” NCT06009627 ↗ “epirubicin hydrochloride IV over 10 minutes” NCT00820547 ↗ “Epirubicin hydrochloride for injection.” NCT07424287 ↗ “epirubicin hydrochloride IV on day 1” NCT00253500 ↗ “Drug: epirubicin hydrochloride” NCT01123473 ↗ “Drug: Epirubicin Hydrochloride” NCT04736394 ↗ “Drug: Epirubicin Hydrochloride” NCT06829199 ↗ “Drug: Epirubicin hydrochloride” NCT06797635 ↗ “Drug: epirubicin hydrochloride” NCT00017186 ↗ “Drug: epirubicin hydrochloride” NCT00055679 ↗ “Drug: epirubicin hydrochloride” NCT00301925 ↗ “Drug: epirubicin hydrochloride” NCT00014222 ↗ “epirubicin hydrochloride” NCT00004873 ↗ “Epirubicin Hydrochloride” NCT05053386 ↗ “epirubicin hydrochloride” NCT00005581 ↗ “epirubicin hydrochloride” NCT00004934 ↗ “epirubicin hydrochloride” NCT00070278 ↗ “epirubicin hydrochloride” NCT00002542 ↗ |
| Known as | Epirubicin, Pfizer | “Epirubicin, Pfizer” NCT01479036 ↗ |
| Known as | Epirubicin: Epirubicin Teva | “Epirubicin: Epirubicin Teva” NCT01301040 ↗ |
| Known as | Epirubicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL417 ↗ |
| Known as | Epirubicine | “Epirubicine, Cyclophosphamide, Paclitaxel” NCT03515798 ↗ |
| Known as | Farmorubicin | “Patients with advanced breast cancer are randomized to first-line chemotherapy with a combination of epirubicin (Farmorubicin®) and paclitaxel (Taxol®) alone (ET) or in...” NCT01433614 ↗1“Epirubicin (Farmorubicin) at the dose of 90mg/m\^2 IV every 3 weeks for 6 consecutive cycles” NCT00431795 ↗ |
| Known as | Farmorubicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL417 ↗ |
| Known as | IMI-28 | ChEMBL registry synonym — accepted as the source's own label CHEMBL417 ↗ |
| Known as | NSC-256942 | ChEMBL registry synonym — accepted as the source's own label CHEMBL417 ↗ |
| Known as | NSC-759195 | ChEMBL registry synonym — accepted as the source's own label CHEMBL417 ↗ |
| Known as | Pharmorubicin | “A: epirubicin, pharmorubicin (EPI) C: cyclophosphamide (CTX） T: paclitaxel (PTX）” NCT03876886 ↗ |
| Known as | WP-697 | ChEMBL registry synonym — accepted as the source's own label CHEMBL417 ↗ |
| Action | Inhibit | “epirubicin also has inhibitory effect on topoisomerase II” NCT03151044 ↗ |
| Modality | Small molecule | “anthracycline-based adjuvant therapy” NCT00162812 ↗ |
| Route | Intravenous | “epirubicin 90 mg/m2 i.v. day 1) every 21 days, intravenous.” NCT00002529 ↗ |